In the last three months, 15 analysts have published ratings on CVS Health (NYSE:CVS), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 8 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 5 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $68.0, a high estimate of $85.00, and a low estimate of $61.00. Witnessing a positive shift, the current average has risen by 6.25% from the previous average price target of $64.00.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of CVS Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Mok | Barclays | Lowers | Overweight | $75.00 | $82.00 |
| David Macdonald | Truist Securities | Raises | Buy | $76.00 | $66.00 |
| Andrew Mok | Barclays | Raises | Overweight | $82.00 | $63.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $75.00 | $62.00 |
| Charles Ryhee | TD Cowen | Raises | Buy | $85.00 | $59.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Ben Hendrix | RBC Capital | Maintains | Outperform | $68.00 | $68.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $62.00 | $62.00 |
| Stephen Baxter | Wells Fargo | Raises | Equal-Weight | $61.00 | $60.00 |
| George Hill | Deutsche Bank | Lowers | Hold | $63.00 | $64.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $63.00 | $65.00 |
| Sarah James | Cantor Fitzgerald | Raises | Neutral | $62.00 | $58.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $62.00 | $65.00 |
Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market. Price Targets: Delving into movements, analysts provide estimates for the future value of CVS Health's stock. This analysis reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVS Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on CVS Health analyst ratings.
Delving into CVS Health's Background
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
Financial Insights: CVS Health
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.6% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's net margin is impressive, surpassing industry averages. With a net margin of 1.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CVS Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.38%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CVS Health's ROA excels beyond industry benchmarks, reaching 0.7%. This signifies efficient management of assets and strong financial health.
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.12.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for CVS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Raymond James | Downgrades | Strong Buy | Outperform |
| Dec 2021 | Tigress Financial | Maintains | Buy | |
| Dec 2021 | Mizuho | Maintains | Buy |
View More Analyst Ratings for CVS
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
